Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
Bracco’s VueJect contrast system secures FDA and Health Canada approvals
Bracco Imaging has obtained 510(k) clearance from the US Food and Drug Administration (FDA) and Health Canada authorisation for VueJect, …
-
First patient in Skylark Bio’s Phase I/II trial receives SKY-GJB2 gene therapy
Skylark Bio has dosed the first patient in its SONIX Phase I/II clinical trial assessing SKY-GJB2 as a potential gene …
-
Alfasigma signs agreement to acquire Nordic Group
Alfasigma has agreed to purchase Nordic Group, a move aimed at strengthening its speciality care business and expanding its reach …
-
AbCellera reports favourable Phase II data for ABCL635
AbCellera has reported encouraging top-line data from the Phase II segment of its Phase I/II study assessing ABCL635, an investigational …
-
Acarix secures approval in UAE for CADScor system
Swedish medical device company Acarix has secured regulatory approval for its CADScor system in the United Arab Emirates (UAE), a …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront
Jazz Pharmaceuticals has signed a definitive agreement to purchase Actio Biosciences in a deal that includes an upfront payment of …
-
RenovoRx reports RenovoCath’s first clinical use in sarcoma
RenovoRx has reported the first commercial clinical use of its RenovoCath device for the treatment of a sarcoma patient. The procedure …
-
Neurocrine begins Phase I trial of NBIP-‘1968 triple agonist for obesity
Neurocrine Biosciences has initiated a Phase I clinical study to evaluate NBIP-'1968, an investigational triple agonist targeting the glucagon-like peptide-1 …
-
Energenesis and Taiwan Tanabe to develop ENERGI-F703DFU for DFUs
Energenesis Biomedical has signed a joint development agreement with Taiwan Tanabe Seiyaku for its investigational topical drug ENERGI-F703DFU to treat …
-
Co-Diagnostics files FDA 510(k) for flu and RSV PCR test
Co-Diagnostics has filed a Dual 510(k) premarket notification with the US Food and Drug Administration (FDA) for its Co-Dx PCR …
-
First patient dosed with DISP-10 in Dispatch Bio’s cancer trial
Dispatch Bio has dosed the first participant in a Phase I clinical trial aimed at evaluating the efficacy and safety …
-
Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases. These conditions …
-
Alteogen signs $365m Hybrozyme licensing deal with pharma company
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide …
-
Azra AI and Blackford partner to connect imaging AI with care coordination
Azra AI and Blackford have formed a partnership to support the progression from imaging-based detection to care coordination for patients …
-
SystImmune doses first patient in Phase III trial for ES-SCLC
SystImmune has dosed the first patient in its global Phase III clinical trial, BrenDeLL-Lung01, assessing BL-M14D1 combined with atezolizumab in …
